Literature DB >> 3765661

The fate of 14C-carbendazim in rat.

J Krechniak, B Kłosowska.   

Abstract

The disappearance of 14C-carbendazim in rat (i.v. 12 mg/kg) followed the kinetics of a two-compartment open-system model. Half-lives of the alpha-phase were 0.1 h (blood), 0.16 h (liver), 0.25 h (kidney), and of the beta-phase: 2.15 h, 6.15 h, respectively. Two metabolites: methyl 5-hydroxy-2-benzimidazolecarbamate (5-HBC) and 2-aminobenzimidazole (2-AB) were formed very rapidly. Their peak concentrations in liver and kidney were 15 min after i.v. injection. Unchanged carbendazim was found in highest concentrations in blood. 5-HBC prevails in organs. 2-AB was present only in minor amounts. The extent of bioavailability in orally administered 14C-carbendazim (12 mg/kg) was about 85%. The disposition of radioactivity in subcellular fractions was not uniform, its highest concentration was in cytosol, the lowest in microsomes. The elimination of 14C-carbendazim in urine is biphasic. Half-lives of the alpha-phase were 1.4 h (i.v.) and 2.5 h (oral), and of the beta-phase 11.2 h and 12.1 h, respectively. Irrespective of the route of administration, 95% of the radioactivity in urine was composed of 5-HBC. The concentration of unchanged carbendazim in blood and of 5-HBC in urine may be of diagnostic value in acute poisoning with carbendazim.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3765661     DOI: 10.3109/00498258609038962

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  1 in total

1.  Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642).

Authors:  Desirée Hao; Jinee D Rizzo; Stephanie Stringer; Rodney V Moore; Jennifer Marty; Daniel L Dexter; Gina L Mangold; James B Camden; Daniel D Von Hoff; Steven D Weitman
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.